Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenretinide for Breast Cancer Prevention in High-Risk Young Women
NCT01479192Phase 3Terminated
- Sponsor
- European Institute of Oncology
- Start
- Dec 2009
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Fenretinide with Placebo (2 arms). Primary endpoint: Breast cancer incidence at 15 years. Started Dec 2009; status: terminated.
02
Drugs
fenretinide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01479192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01479192.